ArticleJournal of the Endocrine Society2023
An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal.
Article in Journal of the Endocrine Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Proposed Definitions and Clinical Recommendations for the Management of Weight Recurrence, Partial Response, and Nonresponse Following Metabolic and Bariatric Surgery.Obesity surgery · 2025Pooled it
- Review
- Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis.Childhood obesity (Print) · 2025Article
- Sex- and Dose-Dependent Effect of L-Citrulline on Body Weight and Food Intake in Obese Type 2 Diabetic Rats.International journal of endocrinology and metabolism · 2025Article
- Evaluation of the impact of a family physician-led lifestyle clinic on overweight and obesity: A clustered randomized trial in Hail, Saudi Arabia.Journal of family medicine and primary care · 2025Article
- Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.Diseases (Basel, Switzerland) · 2025Review
- Nonlifestyle Treatment of Prediabetes.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Article
- Semaglutide for weight loss: unanswered questions.Frontiers in endocrinology · 2024Article
- Should Prediabetes be Treated Pharmacologically?Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Lifestyle and Pharmacological Interventions and Treatment Indications for the Management of Obesity in Children and Adolescents.Children (Basel, Switzerland) · 2023Review
- [Need of a specialised care unit for patients with morbid obesity].Anales del sistema sanitario de Navarra · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite professional society guidelines recommending that obesity be treated as a chronic disease by emphasizing the use of lifestyle modification in conjunction with pharmacotherapy, antiobesity medications are uncommonly prescribed in most clinical practices. The recent Food and Drug Administration approval of semaglutide 2.4 mg weekly to treat obesity-as well as other forthcoming advancements in diabetes and antiobesity medications-highlights the potential of pharmacotherapy to significantly augment weight loss efforts. In this Expert Endocrine Consult, we review the evolving role of antiobesity pharmacotherapy in clinical practice and suggest a framework for the use of these medications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.